Grifols has signed a strategic agreement with Inpeco to provide transfusion medicine labs with complete, tailored ...

Grifols announced on Thursday that it has signed a strategic agreement with Swiss laboratory automation firm Inpeco to provide automated instrumentation, robotics, and software to transfusion medicine ...

Through a pioneering initiative called Chronos-PD, Grifols is partnering with the Michael J. Fox Foundation for Parkinson’s ...

While the company has other operations and these alternative operations are definitely growing, the market share of the $30B per year plasma industry continues to make Grifols an interesting ...

Spanish plasma-derived medicines specialist Grifols (MCE: GRF) has announced positive results from its Phase II/III clinical ...

At the same time, Grifols has formed a strategic alliance with Haier in the market for plasma products, particularly albumin, and diagnostics. It has been involved in a series of acquisitions in ...

Grifols, S.A. (NASDAQ:GRFS) is a Spanish global healthcare company specializing in plasma-derived therapies, diagnostics, and hospital pharmacy products. The company was founded in 1909 in ...

More than two dozen people rallied on Monday against a new for-profit clinic in Whitby that pays people for plasma donations. Demonstrators marched outside the office of the Grifols Plasma ...

Recent human trials of a new one-year-long immune-based treatment for post-polio syndrome, which can strike polio survivors ...

leading to new diagnostic tools and disease-modifying therapiesPart of broad Grifols program to find disease-revealing clues in more than 100 million proprietary plasma samples connected to real ...

Grifols has shared positive results from its clinical trial evaluating the efficacy and safety of intravenous immunoglobulin to treat patients with PPS.